These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36456600)

  • 1. Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.
    Mansour S; Adhya I; Lebleu C; Dumpati R; Rehan A; Chall S; Dai J; Errasti G; Delacroix T; Chakrabarti R
    Sci Rep; 2022 Dec; 12(1):20725. PubMed ID: 36456600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
    Denholt CL; Hansen PR; Pedersen N; Poulsen HS; Gillings N; Kjaer A
    Biopolymers; 2009 Mar; 91(3):201-6. PubMed ID: 19107925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of a novel human scFv inhibiting EGFR vIII expressing cancers.
    Rahbarnia L; Farajnia S; Babaei H; Majidi J; Dariushnejad H; Hosseini MK
    Immunol Lett; 2016 Dec; 180():31-38. PubMed ID: 27984065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery.
    Furman O; Zaporozhets A; Tobi D; Bazylevich A; Firer MA; Patsenker L; Gellerman G; Lubin BCR
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.
    McIntyre JB; Bose P; Klimowicz AC; Brockton NT; Petrillo S; Matthews W; Easaw J; Magliocco A; Dort JC
    PLoS One; 2012; 7(2):e31723. PubMed ID: 22359620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Human Single Chain Antibody Against EGFRVIII Antigen by Phage Display Technology.
    Rahbarnia L; Farajnia S; Babaei H; Majidi J; Akbari B; Ahdi Khosroshahi S
    Adv Pharm Bull; 2016 Dec; 6(4):563-571. PubMed ID: 28101463
    [No Abstract]   [Full Text] [Related]  

  • 10. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
    Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
    Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
    Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
    J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
    Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
    Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
    Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
    Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
    Lorimer IA; Keppler-Hafkemeyer A; Beers RA; Pegram CN; Bigner DD; Pastan I
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14815-20. PubMed ID: 8962138
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.